Literature DB >> 7964690

Changes in aminergic receptors in a PSP postmortem brain: correlation with pathological findings.

J Pascual1, J Figols, B Grijalba, A M González, E del Olmo, J Berciano, A Pazos.   

Abstract

The state of different aminergic receptors was assessed, by quantitative autoradiography in tissue sections, in several representative brain regions from a typical progressive supranuclear palsy (PSP) patient and from 9 matched brains. The densities of muscarinic receptors were within control limits in most of the brain areas of this PSP brain. Serotonin1 receptors were clearly reduced only in areas with very relevant neuropathological damage, such as locus niger and globus pallidus. The density of D1 dopamine receptors in the caudate-putamen and frontal cortex of the patient was within control limits. By contrast, nigral D1 and striatal D2 dopamine receptors were dramatically reduced in the patient as compared to controls. Finally, alpha 2-adrenoceptors were clearly reduced in all the examined areas of this PSP patient as compared to control group. Both the potential role of these receptor changes in the pathophysiology of the clinical features of PSP and their correlation with the neuropathological findings of this PSP patient are discussed.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7964690     DOI: 10.1007/978-3-7091-6641-3_19

Source DB:  PubMed          Journal:  J Neural Transm Suppl        ISSN: 0303-6995


  2 in total

1.  A novel computer-assisted image analysis of [123I]β-CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders.

Authors:  Georg Goebel; Klaus Seppi; Eveline Donnemiller; Boris Warwitz; Gregor K Wenning; Irene Virgolini; Werner Poewe; Christoph Scherfler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-12-21       Impact factor: 9.236

2.  The basal ganglia cholinergic neurochemistry of progressive supranuclear palsy and other neurodegenerative diseases.

Authors:  N M Warren; M A Piggott; A J Lees; D J Burn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-12-18       Impact factor: 10.154

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.